Connect with us

BUSINESS

Kannaway, A Subisidiary Of Medical Marijuana Inc (OTCMKTS:MJNA), Expands Into Kyrgyzstan, Kazakhstan, And Russia: Kannway Issues An Update On Newly Acquired Patents

Published

on

Kannaway, a subsidiary of Medical Marijuana Inc (OTCMKTS:MJNA), has expanded its operations into Kyrgyzstan, Kazakhstan, and Russia. With this expansion, the company can now satisfy the demand for cannabis-derived nutraceutical products. Commenting on the expansion into these nations, Blake Schroeder, Chief Executive Officer of Kannaway, said it is an example of how it opens and develops markets across the world. The expansion helps the company to get a pie of the $17.4 billion worth CBD nutraceuticals market worldwide.

Becomes the first direct selling company

Kannaway is the first direct selling company to provide hemp-derived CBD products in Europe and the US. It now sells products in more than thirty nations that include across the US and in Europe. The company’s expansion is part of aggressive overseas expansion plans. It already expanded into the Asian market in June 2019.

The expansion into Kyrgyzstan, Kazakhstan, and Russia will help the consumers to try its products. Chief Executive Officer of Medical Marijuana, Dr. Stuart Titus, said people worldwide should access its CBD products irrespective of the geographic location. The brand ambassadors of Kannaway in these nations can now establish back office accounts and also access the website assets of Kannaway in their mother tongue. They can read event pages, news, and blogs in their language.

An update on newly acquired patents

Kannalife Inc., an investment portfolio company of Medical Marijuana, has issued an update on its IP (intellectual property) with the title “Novel Functionalized 1, 3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy”.

Titus said the company is pleased to have Kannalife as an investment portfolio company because Medical Marijuana is achieving new heights in the research of cannabinoid therapeutics. The company conducted a lot of research last year in the cannabis space. However, a lot needs to be done in this space, and Kannalife provides support in its endeavors.

Kannalife receives patent approval

Kannalife has obtained patent approval for the treatment of hepatic encephalopathy, and novel functionalized 1, 3 Benzene Diols and their methods to cure hepatic encephalopathy in the US. The company also achieved patents in Russia and Japan for the same treatments.

The applications submitted by Kannalife for protecting the IP are accepted in nations – Australia, China, and the EU. It also awaits notice of acceptance from India, Brazil, and Canada.

BUSINESS

Sugarmade Inc (OTCMKTS:SGMD) Announces A Sharp Increase In Demand For Cannabis Delivery Service: Reports A 10% Weekly Sales Increase

Published

on

Sugarmade Inc (OTCMKTS:SGMD) has announced a significant rise in demand for its cannabis delivery service. It witnesses a 10% rise in weekly sales in the past two weeks because of growing coronavirus pandemic. The stay at the home trend is contributing to the significant demand for cannabis medicines. Several people are stocking one-month medicines as a precautionary measure.

The demand for cannabis service to continue

Sugarmade anticipates that the demand for cannabis delivery service will continue for several weeks. To meet the growing demand, Budcars is expanding its headcount. The company expects to solidify its yearly revenue target of $20 million in 2020 because of a sharp jump in sales.

Controlling stake in BudCars

Chief Executive Officer of Sugarmade, Jim Chan, said the COVID-19 is creating a change in the consumer behavior pattern. It will have a long term impact. Sugarmade recently acquired a significant stake in BudCars. It keeps opening an option to acquire a controlling stake in BudCars.

BudCars is well-positioned to clinch a large portion of the rapidly growing delivery service and mobile commerce. Several people shift to the home delivery option. Therefore, cannabis is not an exception. BudCars is prepared to cash in on this growing demand for cannabis delivery.

Growing demand for courier services

According to the management, the outbreak of COVID-19 has increased demand for virtual connectivity, home delivery of goods/ services, and online consumption. The same trend expects to continue for several weeks. It has created a growing demand for companies such as Instacart, Postmates, and Amazon and several other courier services. This trend also applies to the legal cannabis market in California.

Chan said the company is experiencing a growing demand for increased order size for edibles and flower and cannabis deliveries because several customers are stocking up for an extended period at home. According to the CDC recommendation, they are stocking up medicines for at least 30 days.

Enhanced safety practices

BudCars is taking precautions to ensure safety to the customers and its delivery staff. The company, along with Sugarmade, has ramped up cannabis delivery service in the Sacramento metropolitan area. The company will extend its reach to meet the growing demand.

Continue Reading

BUSINESS

Cure Pharmaceutical Holding Corp (OTCMKTS:CURR) Receives A Chinese Patent To Load High Amounts Of Active Drug On Oral Thin Film To Cure ED In China

Published

on

Cure Pharmaceutical Holding Corp (OTCMKTS:CURR) is pleased to announce the receipt of a Chinese Patent No. ZL201480039313.6. The new patent allows the company to load a high amount of active drug on a soluble thin film using its drug delivery system to cure erectile dysfunction in China.

Demand for erectile dysfunction treatment

Cure Pharmaceutical shall deliver Viagra through oral administration using its CUREfilm Blue to treat ED in China. The demand for erectile dysfunction treatment expects to reach $6.5 billion by the year 2025. Chief Executive Officer of Cure Pharmaceutical, Rob Davidson, said the receipt of vital Chinese patent helps its global commercialization efforts for CUREFilm Blue and other drugs that will be delivered using this technology. Cure Pharmaceutical targets CUREFilm Blue at Asian markets, mainly China, where high demand for ED exists.

According to QY Research, Asia Pacific is one of the fastest-growing markets for the medicine to treat ED. Viagra accounts for half of global sales. The Chinese patent covers innovative methods of preparing edible thin films, which helps to deliver higher dosages of active ingredients. Cure Pharmaceuticals could differentiate its thin-film products from other oral soluble films that deliver sildenafil.

Signs a collaboration accord with Vanguard Scientific

Cure Pharmaceutical has signed a collaboration and license agreement with Vanguard Scientific Systems Inc. With this licensing agreement, Vanguard can get access to the Cure Pharmaceutical’s cannabis extraction methods. It improves the confidence to customers in using Vanguard’s extraction manufacturers.

Davidson said the agreement provides operational freedom to Vanguard, which is a leading player in the supercritical fluid extraction methods, to maintain pharma-grade standards using the licensing strategy of Cure Pharmaceutical. It will collaborate with Vanguard for expanding the patent to cover the latest advances in the field.

Vanguard could make use of the Cure Pharmaceutical’s issued and pending process as well as composition patents to separate cannabinoids with the help of supercritical fluid extraction technology. The isolation of cannabinoids is established using the solvent – Carbon dioxide.

The patent allows the insertion of cannabis extracts in various dosage forms. However, Cure Pharmaceutical reserves the right to apply these techniques in an oral film. Chief Executive Officer of Vanguard, Matthew Anderson, said his customers will enjoy peace of mind when choosing extraction solutions of Vanguard.

Continue Reading

BUSINESS

Novus Acquisiti (OTCMKTS:NDEV) Reports Revenues Of $57,862 In Q4 2019

Published

on

Novus Acquisiti (OTCMKTS:NDEV) has reported robust revenues of $57,862 in Q4 2019. It is an increase of 17.2% when compared to the same period last year. The company has posted revenues of $219,240 in 2019. It represents an increase of 22% when compared to the previous year.

Improves In-network providers

Chief Executive Officer of Novus, Frank Labrozzi, said the company demonstrated continued growth in 2019 and expects to continue the same momentum in 2020. It sees an increase in the commercialization of the Cannabis Health Plan and expects to record phenomenal growth. In nine states, which legalized THC, the company has improved its In-Network providers.

Uninsured Non-Elderly Americans

Novus expects continued growth for its plans from uninsured and non-elderly Americans. It expects a total of 30 million from this segment. Several people in this bracket are uninsured and spend over one-third of the money from their pockets in the whole year. Novus has a presence in states like Illinois, Colorado, Nevada, Arizona, and California in which the uninsured rates 10% or higher. Many people in these states are uninsured because of the cost of health insurance is very high.

Expanding network of THC providers

Novus is expanding its network of THC providers that services its members/ patients in areas offering state-wide and city-wide delivery options. The providers of CBD offer delivery of CBD nationwide.

Signs an MGA agreement with Healthfield Solutions

Novus has announced the signing of an MGA accord with Healthfield Solutions, LLC, to sell its Cannabis Med Plan. Apart from marketing Novus Cannabis Med Plan along with its life, dental and supplemental health plans, Healthfield also trains its 1,600 agents. Its client base is more than 250,000.

Cannabis companies engaged in the cultivation and extraction are under pressure from the shareholders to increase profitability. Novus helps such companies with its tailored health plans say usage-based health plans. The companies can offer discounts/ rebates to the customers using Novus tailored health plans. Therefore, Verticals can offer affordable cannabis meds to their members and improve volumes and maintain higher profits.

Novus offers two plans: 1) offer a higher discount and also increase cannabis list price, 2) a higher markdown, and earn less money on cannabis meds sale. Most of the Verticals select the first plan to improve their margins.

Continue Reading



Trending Stories